CancerDrs Find care

Liver Cancer clinical trials in Oklahoma

10 actively recruiting liver cancer trials at 3 sites across Oklahoma.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Industry

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in comb…

Sponsor: AstraZeneca
NCT ID: NCT06921785
Sites in Oklahoma:
  • Research Site — Oklahoma City, Oklahoma
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis

The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-p…

Sponsor: Genentech, Inc.
NCT ID: NCT06096779
Sites in Oklahoma:
  • The University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

This phase II trial tests how well giving durvalumab with standard chemotherapy, gemcitabine and cisplatin, before surgery works in treating patients with high risk liver cancer (cholangiocarcinoma) that can be removed by surgery (resectab…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06050252
Sites in Oklahoma:
  • University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

The primary objectives of Cohort A Phase 1b and exploratory expansion are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and unresectable Hepato…

Sponsor: Tvardi Therapeutics, Incorporated
NCT ID: NCT05440708
Sites in Oklahoma:
  • University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Combination of TATE and PD-1 Inhibitor in Liver Cancer

This is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (nivolumab). Patients with t…

Sponsor: Teclison Ltd.
NCT ID: NCT03259867
Sites in Oklahoma:
  • University of Oklahoma Health Science Center — Oklahoma City, Oklahoma
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Liver Cancer Disparities in American Indian and Alaska Native Persons

We are performing a pilot and feasibility randomized controlled trial (RCT) of HCC screening by US + AFP every 6 months (n=100), the current standard-of-care, versus aMRI + AFP every 6 months (n=100) for 12 months (i.e. at time 0, 6 and 12…

Sponsor: University of Washington
NCT ID: NCT05304234
Sites in Oklahoma:
  • Cherokee Nation Health Service — Tahlequah, Oklahoma
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Oklahoma:
  • Massive Bio SYNERGY-AI site — Tulsa, Oklahoma
View on ClinicalTrials.gov →
NA Recruiting NIH

The Vanguard Study: Testing a New Way to Screen for Cancer

The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for mult…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06995898
Sites in Oklahoma:
  • University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20